Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data
Authors:
- Joseph R CalabreseJCJoseph R Calabrese
- the Agomelatine Bipolar Study GroupTGthe Agomelatine Bipolar Study Group
- 5 September 2007
- journal article
- clinical trial
- Published by Wiley in Bipolar Disorders
- Vol. 9 (6) , 628-635
Abstract
Objectives: Agomelatine has been shown to be safe and efficient in the treatment of major depressive disorder at 25 mg daily. The aim of this study was to gather preliminary data regarding the antidepressant efficacy of agomelatine in patients with bipolar I disorder experiencing a major depressive episode.Methods: Bipolar I patients on lithium (n = 14) or valpromide (n = 7), with a Hamilton Rating Scale for Depression (HAM‐D‐17) total score ≥ 18, were given adjunctive open‐label agomelatine at 25 mg/day for a minimum of 6 weeks followed by an optional extension of up to an additional 46 weeks.Results: Using intent‐to‐treat data, 81% of patients met criteria for marked improvement (>50% improvement from baseline in HAM‐D score) at study endpoint. Patients were severely depressed at study entry (HAM‐D of 25.2) and 47.6% responded as early as at one week of treatment. Nineteen patients entered the optional extension period for a mean of 211 days (range 6–325 days). Eleven patients completed the one‐year extension on agomelatine. There were no dropouts due to adverse events during the acute phase of treatment (6 weeks). Six patients experienced serious adverse events during the one‐year period. Three lithium‐treated patients experienced manic or hypomanic episodes during the optional extension period, one of which was treatment‐related.Conclusions: These results indicate the effectiveness of agomelatine 25 mg in the treatment of depressed bipolar I patients co‐medicated with lithium or valpromide. A randomized controlled trial is planned to confirm these results.Keywords
This publication has 25 references indexed in Scilit:
- Placebo-controlled trial of agomelatine in the treatment of major depressive disorderEuropean Neuropsychopharmacology, 2006
- Costs of Bipolar DisorderPharmacoEconomics, 2003
- Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range studyInternational Clinical Psychopharmacology, 2002
- Sleep phase advance and lithium to sustain the antidepressant effect of total sleep deprivation in bipolar depression: new findings supporting the internal coincidence model?Journal of Psychiatric Research, 2001
- Double-Blind, Placebo-Controlled Comparison of Imipramine and Paroxetine in the Treatment of Bipolar DepressionAmerican Journal of Psychiatry, 2001
- I Know This Much Is TrueAmerican Journal of Psychiatry, 2000
- Antidepressant Discontinuation-Related ManiaThe Journal of Clinical Psychiatry, 1999
- Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependentPharmacology Biochemistry and Behavior, 1996
- Melatonin analogues as agonists and antagonists in the circadian system and other brain areasEuropean Journal of Pharmacology, 1996
- Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS)Pharmacology Biochemistry and Behavior, 1993